SYSTEMATIC REVIEW

Prevalence and implications of frailty in acute stroke: systematic review & meta-analysis

JENNIFER K. BURTON1, JENNIFER STEWART2, MAIRI BLAIR3, SINEAD OXLEY2, AMY WASS4, MARTIN TAYLOR-ROWAN1, TERENCE J. QUINN1

1Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK
2Glasgow Royal Infirmary, NHS Greater Glasgow and Clyde, Glasgow, UK
3Queen Elizabeth University Hospital, NHS Greater Glasgow and Clyde, Glasgow, UK
4Forth Valley Royal Hospital, NHS Forth Valley, Larbert, UK

Address correspondence to: Terence J. Quinn, Academic Section of Geriatric Medicine, Room 2.44 New Lister Building, Glasgow Royal Infirmary, 10 Alexandra Parade, G31 2ER. Email: terry.quinn@glasgow.ac.uk

Abstract

Background: frailty is common in older adults and associated with poor outcomes following illness. Although stroke is predominantly a disease of older people, our knowledge of frailty in stroke is limited. We aimed to collate the literature on acute stroke and frailty to estimate the prevalence of pre-stroke frailty and its associations with outcomes.

Methods: paired researchers searched multidisciplinary electronic databases for papers describing frailty and acute stroke. We assessed risk of bias using Newcastle-Ottawa tools appropriate to study design. We created summary estimates of pre-stroke frailty using random effects models. We collated whether studies reported significant positive associations between frailty and clinical outcomes in adjusted models.

Results: we included 14 studies (n = 27,210 participants). Seven studies (n = 8,840) used a frailty index approach, four studies (n = 14,924) used Hospital Frailty Risk Scores. Pooled prevalence of pre-stroke frailty was 24.6% (95% confidence interval, CI: 16.2–33.1%; low quality evidence, downgraded due to heterogeneity, bias). Combining frailty and pre-frailty (nine studies, n = 23,827), prevalence of any frailty syndrome was 66.8% (95%CI: 49.9–83.7%). Seven studies were at risk of bias, from participant selection or method of frailty assessment. Pre-stroke frailty was associated with all adverse outcomes assessed, including longer-term mortality (positive association in 6 of 6 studies reporting this outcome; odds ratio: 3.75 [95%CI: 2.41–5.70]), length of admission (3 of 4 studies) and disability (4 of 6 studies).

Conclusions: despite substantial heterogeneity, whichever way it is measured, frailty is common in patients presenting with acute stroke and associated with poor outcomes. This has implications for the design of stroke services and pathways.

Keywords: disability, frailty, prevalence, mortality, stroke, older people

Key Points

- Prevalence of pre-stroke frailty is around one in four in an acute stroke population.
- There is little consistency in the methods used to assess for pre-stroke frailty.
- Pre-stroke frailty is independently associated with a variety of poor outcomes.
- Although related, pre-stroke frailty is not synonymous with pre-stroke functional ability or comorbidity.
- Standardised frailty assessment in stroke may inform treatment decisions, prognostics and design of patient centred services.
J. K. Burton et al.

Introduction
An understanding and consideration of frailty is of fundamental importance in the care of the unwell older adult [1]. In older adults presenting with acute illness, frailty is common, quantifiable and strongly associated with poor outcomes [2]. In recognition of this, many international healthcare systems are incorporating measures of frailty into their acute care pathways [3]. Stroke is one of the more common acute presentations seen in older adults, yet assessment of frailty is not yet standard in stroke-care, and best practice guidance on frailty rarely mentions stroke [3]. A first step in understanding the relationship between frailty and stroke is to have a benchmark figure for the prevalence of frailty in people presenting with stroke.

Despite advances in stroke-care, stroke has a persistently high mortality and can leave survivors with disability or requiring care-home admission. Predicting outcomes at the time of acute stroke is difficult [4, 5]. However, frailty is associated with many of the poor outcomes seen in stroke [6] and assessment of frailty may aid prognostication.

There is a strong association between pre-stroke function, usually measured using the modified Rankin Scale (mRS), and stroke outcomes [7]. Assessment of pre-stroke mRS is recommended to inform decisions around hyperacute therapies such as intravenous thrombolysis or mechanical thrombectomy, but is an imperfect tool [8]. Plausibly a measure of frailty may have greater prognostic utility and be less prone to the limitations of the mRS. Conversely, it could be argued that pre-stroke function is already a suitable proxy for frailty, or that describing pre-stroke frailty adds little to the mRS assessment.

Our overall aim was to describe frailty in an acute stroke population.

Specific objectives were to estimate the prevalence of pre-stroke frailty; describe the association between pre-stroke frailty and clinical outcomes and assess relationships between pre-stroke frailty and pre-stroke function or morbidity.

Methods
This review was reported following Preferred Reporting of Items in Systematic Reviews and Meta-Analyses (PRISMA) guidance. The protocol was registered in 2019 (CRD: 42019154402: https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=154402).

Each aspect of the review process was performed by at least two experienced reviewers with access to a third party as required.

Eligibility criteria
We placed no restrictions on date or language of publication. If abstracts were identified, we searched for subsequent full-text publications using author names and abstract titles.

Population
We included studies of adults (aged 16 years and older) with stroke presentations (any stroke subtype, but not including transient ischaemic attack (TIA), subarachnoid or subdural haemorrhage). We accepted any definition of ‘acute’ stroke, but did not include studies that recruited from rehabilitation or community settings.

Exposure
We included any measure that the authors described as a frailty assessment, provided that the intention was to quantify frailty status before the stroke event. We included studies if they reported either frailty prevalence or quantitative data describing association between frailty and our prespecified outcomes.

Outcomes
Our pre-specified outcomes of interest were mortality (in-hospital, 30 days and 1 year), length of hospital stay, functional outcome and discharge destination. Where other clinical outcomes were described, we noted these.

Study types
We included prospective and cross-sectional studies and adapted data extraction accordingly.

Information sources
We searched MEDLINE (Ovid); EMBASE (Ovid), CINAHL (EBSCOhost), PsycInfo (EBSCOhost) and Health Management Information Consortium (Ovid) from 1980 to September 2020. The search was developed using the Cochrane search filter for stroke studies and a bespoke syntax for frailty (Appendix 1, Supplementary data are available in Age and Ageing online). We included papers that were published after the initial search but were identified through forward searching or other strategies.

Study selection and data collection
We used Covidence software for de-duplication and title searching [9]. We developed a data extraction form and piloted this against two papers, to ensure authors were familiar with the required data content and format. As a further quality control step, after paired review, a third author double-extracted a random sample (25%) of papers.

Data were extracted on study design, frailty assessment and outcomes, noting any data regarding pre-stroke function or quantitative measures of comorbidity.

Risk of bias assessment
Risk of bias was assessed based on the Newcastle-Ottawa Scale, using the tool for cohort studies or cross-sectional studies as required and modifying the anchoring statements.
to suit the review question (Appendix 2, Supplementary data are available in Age and Ageing online; [10]). In keeping with best practice, we present a narrative assessment of risk of bias, rather than a summary score [11].

**Synthesis of results**

We categorised frailty as a binary variable to enable calculation of summary prevalence estimates. Where a scale used hierarchical categorisation, for example mild, moderate and severe frailty, for the primary analysis we classified those in the most severe category as frail. Where available we also collected data on pre-frailty and for nominal, hierarchical scales we used the category below that which was used to define frank frailty. Where uncertainty in the prevalence estimate was not reported in the original paper, we derived a 95% confidence interval (95%CI) using prevalence and sample size.

We used Comprehensive Meta-Analysis software [12] to generate a summary estimate of frailty and pre-frailty prevalence pooled across the included studies using random effects models.

We ran subgroup analyses limited to commonly employed frailty measures and sensitivity analyses where we excluded highly selected populations. As a post-hoc exploratory analysis, we created a summary estimate of strength of association between frailty and mortality.

We assessed heterogeneity using the $I^2$ statistic and created a funnel plot to visually inspect for publication bias.

We described certainty in our estimate of pre-stroke frailty using the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) framework. We modified the GRADE approach for observational epidemiology assessing for bias, consistency (based on $I^2$), directness (applicability of included studies to pre-stroke frailty), precision (based on uncertainty of the summary estimate) and publication bias (funnel plot).

We described associations of pre-stroke frailty as a narrative, tabulated strength of association and complemented this with a data visualisation approach where we displayed all studies that assessed adjusted associations of pre-stroke frailty against clinical outcomes.

We tabulated data on the prevalence of pre-stroke functional impairment or quantitative measures of comorbidity as described by the authors. If not already reported in the paper, and where data allowed, we compared proportional prevalence of pre-stroke disability or comorbidity with pre-stroke frailty.

**Results**

We screened 2,504 records by title and abstract after de-duplication [9]. We assessed 51 studies in full and included 16 publications representing 14 studies [13–28]. We identified an additional 12 conference abstracts that were potentially eligible for inclusion, but with no corresponding full-text publication (Appendix 3, Supplementary data are available in Age and Ageing online; [29–40]). We excluded 23 studies with main reasons for exclusion including, no frailty data and not an acute stroke population (Appendix 4, Supplementary data are available in Age and Ageing online).

**Included study characteristics**

Included study characteristics are summarised in Table 1. Included studies were mainly cohort designs, with two cross-sectional studies. Two studies had multiple publications using the same underlying dataset and data from all were used as needed [17, 18, 25, 26]. All studies were hospital based, seven were single-centre and all recruited from industrialised countries. Sample sizes varied from 156 to 12,019 participants with mean sample size 2,221 participants. The average age of participants was between 64 and 87 years. Men accounted for 39–63% of participants. Five studies only included ischaemic stroke and three included only haemorrhagic stroke. Ten of the included studies provided baseline stroke severity using National Institutes of Health Stroke Scale (NIHSS) with scores ranging from 1 to 20.

Characteristics of the 12 studies reported in abstract format alone are summarised in Appendix 3, Supplementary data are available in Age and Ageing online. There was duplication of reporting with data from the same underlying study cohorts in 3 of the 12. Sample sizes varied from 33 to 3,965 participants, with most studies describing ischaemic stroke populations.

**Risk of bias within studies**

Complete risk of bias assessment is presented in Table 2. Seven studies had at least one domain graded as high risk. All of these studies had problems with patient selection due to unnecessary exclusions [17]; a focus on intracerebral haemorrhage patients only [15, 20, 28] and recruitment limited to those offered mechanical thrombectomy [12, 18, 19]. In three studies [11, 18, 19] the method used to assess for pre-stroke frailty may have included post stroke complications. In three studies [11, 16, 19], there may not have been sufficient time for outcomes to develop, these were generally studies that assessed in-hospital outcomes only.

**Measurement of frailty**

There was considerable heterogeneity across the included studies in the tool used to assess frailty and how this was defined and classified (Table 3). Seven studies used an approach based on frailty index (varying number of items included, range: 4–33; [14–17, 20, 24, 25]) four studies used the Hospital Frailty Risk Score [19, 22, 23, 28], albeit with differing terminology for the included categories; two used the Fried phenotype approach [25, 27], one used pre-stroke mRS [21] and one study used the Clinical Frailty Scale (CFS; [13]). One study compared two measures of frailty in the same cohort, a 33-item frailty index and the Fried phenotype, although there was substantial missing phenotype data [25]. The other author team who adapted
<table>
<thead>
<tr>
<th>Study ID</th>
<th>Country</th>
<th>Sample size</th>
<th>Setting</th>
<th>Age</th>
<th>Male sex (%)</th>
<th>Stroke subtype</th>
<th>Stroke severity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Evans 2020 [13]</td>
<td>England</td>
<td>433</td>
<td>Single hospital</td>
<td>Median</td>
<td>43.8</td>
<td>Ischaemic stroke only</td>
<td>Median baseline NIHSS</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Frail 87</td>
<td></td>
<td>[83–92]</td>
<td></td>
</tr>
<tr>
<td>Fearon 2012 [14]</td>
<td>Scotland</td>
<td>231</td>
<td>Single hospital</td>
<td>Median</td>
<td>NR</td>
<td>NR</td>
<td>TACS 20%</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>74 [63–82]</td>
<td></td>
<td>PACS 27%</td>
<td>LACS 40%</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>POCS 10%</td>
<td></td>
</tr>
<tr>
<td>Imaoka 2018 [15]</td>
<td>Japan</td>
<td>156</td>
<td>Multiple hospitals</td>
<td>Mean</td>
<td>58.9</td>
<td>Haemorrhagic stroke only</td>
<td>NR</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>66.0 ± 13.4</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Joyce 2021 [16]</td>
<td>Northern Ireland</td>
<td>175</td>
<td>Single hospital</td>
<td>Mean</td>
<td>43</td>
<td>Ischaemic stroke only</td>
<td>Median Baseline NIHSS</td>
</tr>
<tr>
<td>Kilkenny 2021 [19]</td>
<td>Australia</td>
<td>12,019</td>
<td>Multiple hospitals</td>
<td>Median</td>
<td>53.6</td>
<td>82.6% ischaemic</td>
<td>NR</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>75.8</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kim 2020 [20]</td>
<td>USA</td>
<td>240</td>
<td>Single hospital</td>
<td>Mean</td>
<td>53.8</td>
<td>Haemorrhagic stroke only</td>
<td>NR</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>68.5 ± 14.2</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Myint 2017 [21]</td>
<td>England</td>
<td>2,388</td>
<td>Multiple hospitals</td>
<td>Mean</td>
<td>47.3</td>
<td>87% ischaemic</td>
<td>TACS 21.5%</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>76.9 ± 12.7</td>
<td></td>
<td>PACS 27.6%</td>
<td>LACS 24.8%</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>POCS 14.1%</td>
<td></td>
</tr>
<tr>
<td>Pinho 2021 [22]</td>
<td>Germany</td>
<td>489</td>
<td>Multiple hospitals</td>
<td>Median</td>
<td>49.5</td>
<td>Ischaemic stroke only</td>
<td>Median Baseline NIHSS</td>
</tr>
<tr>
<td>Schneider 2021 [23]</td>
<td>Germany</td>
<td>318</td>
<td>Single hospital</td>
<td>Median</td>
<td>39.6</td>
<td>Ischaemic stroke only</td>
<td>Median Baseline NIHSS</td>
</tr>
<tr>
<td>Scamon 2019 [24]</td>
<td>USA</td>
<td>7,258</td>
<td>Multiple hospitals</td>
<td>Mean</td>
<td>43.3</td>
<td>Ischaemic stroke only</td>
<td>SASI</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>79.4 ± 8.4</td>
<td></td>
<td></td>
<td>Severe 22.1%</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Moderate 32.9%</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Mild 45%</td>
</tr>
<tr>
<td>Taylor-Rowan 2019 [25, 26]</td>
<td>Scotland</td>
<td>546</td>
<td>Single hospital</td>
<td>Mean</td>
<td>54</td>
<td>NR</td>
<td>Median Baseline NIHSS</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>64 ± 14</td>
<td></td>
<td>Non-frail 3 [1–5]</td>
<td>Frail 4 ± 3.9</td>
</tr>
<tr>
<td>Waehler 2021 [27]</td>
<td>Norway</td>
<td>625</td>
<td>Multiple hospitals</td>
<td>Mean</td>
<td>57.9</td>
<td>91.8% ischaemic</td>
<td>Mean Baseline NIHSS</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>66 ± 11.6</td>
<td></td>
<td>Non-frail 3 [1–5]</td>
<td>Robust 1.8 ± 3.9</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Pre-frail 73</td>
<td></td>
<td></td>
<td>Prefrail 3 ± 4</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>±10.6</td>
<td></td>
<td></td>
<td>Frail 4 ± 3.9</td>
</tr>
<tr>
<td>Zhang 2020 [28]</td>
<td>Australia</td>
<td>2098</td>
<td>Multiple hospitals</td>
<td>Median</td>
<td>52</td>
<td>Haemorrhagic stroke only</td>
<td>NR</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>81 ± 7.2</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>76 [65,84]</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; CVD, cardiovascular disease; LACS, lacunar strokes; NIHSS, National Institute for Health Stroke Scale; NR, not reported; PACS, partial anterior circulation strokes; POCS, posterior circulation strokes; PVD, peripheral vascular disease; SASI, Stroke Administrative Severity Index; TACS, total anterior circulation strokes. Q1–Q3 or interquartile range presented in square brackets based on reporting within individual papers with median results; standard deviation of mean results denoted by ±.
the Fried phenotype criteria for application in stroke, also reported problems with completion [27].

The definition used to classify an individual’s frailty status was not explicitly provided in three of the included studies [15, 20, 21]. For two of these studies, a modified frailty index was treated as a continuous variable [15, 20], we were able to extrapolate a frailty prevalence for one of these. The other study defined frailty based on pre-stroke mRS assessment [21]. For the purpose of the analysis, we assumed that frailty status would be based on a mRS > 2.

Among the abstracts, four used a frailty index approach [29, 30, 38, 39], three used the CFS [32, 36, 37], one used pre-stroke mRS [40], one used Fried phenotype criteria [33], one used comprehensive geriatric assessment (CGA [34]), one used the Canadian Study on Health and Ageing Scale [35] and one provided their own definition of frailty [31].

**Frailty prevalence**

Treating frailty as a binary construct, the prevalence of frailty varied from 2.2 to 54% of included participants. The pooled summary estimate for the prevalence of frailty in stroke was 24.6% (95%CI: 18.1–35.4%; I²: 94.8%); 13 studies; 27,054 participants; Figure 1). Funnel plot suggested no publication bias (Appendix 5, Supplementary data are available in Age and Ageing online). Using the GRADE framework, certainty of evidence was low due to problems with heterogeneity and risk of bias.

Pre-frailty prevalence was described in nine of the included studies, ranging from 11.3 to 68.3%. The pooled summary estimate for pre-frailty was 45.5% (95%CI: 34.6–56.4%; I²: 92.1%); nine studies; 23,827 participants). Combining frailty and pre-frailty, prevalence of any frailty syndrome pre-stroke was 66.8% (95%CI: 49.9–83.7%; I²: 98.0%); nine studies; 23,827 participants). Combining those studies where only frailty was described and those with frailty and pre-frailty, the summary estimate was 56.6% (95%CI: 39.0–74.1%; I²: 98.7%); 13 studies; 27,054 participants).
Table 3. Summary table of quality assessment of included studies

<table>
<thead>
<tr>
<th>Study ID</th>
<th>Design</th>
<th>SELECTION</th>
<th>COMPARABILITY</th>
<th>OUTCOME</th>
</tr>
</thead>
<tbody>
<tr>
<td>Evans 2020[13]</td>
<td>Prospective cohort</td>
<td>Yes Yes Yes Yes</td>
<td>Yes Yes Yes</td>
<td>Unclear</td>
</tr>
<tr>
<td>Imaoka 2018[15]</td>
<td>Retrospective cohort</td>
<td>No Yes Yes Yes</td>
<td>Yes Yes Yes</td>
<td>No</td>
</tr>
<tr>
<td>Joycee2021[16]</td>
<td>Prospective cohort</td>
<td>No Yes Yes Yes</td>
<td>Yes Yes Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Kilkenny 2021[19]</td>
<td>Retrospective cohort</td>
<td>Yes Yes Yes Yes</td>
<td>Yes Yes Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Kim 2020[20]</td>
<td>Retrospective cohort</td>
<td>No Yes Yes Yes</td>
<td>Yes Yes Yes</td>
<td>No</td>
</tr>
<tr>
<td>Myint 2017[21]</td>
<td>Retrospective cohort</td>
<td>Yes Yes Yes Yes</td>
<td>Yes Yes Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Noguchi 2021[18]</td>
<td>Prospective cohort</td>
<td>No Yes Yes Yes</td>
<td>Yes Yes Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Pinho 2021[22]</td>
<td>Retrospective cohort</td>
<td>No Yes Yes Yes</td>
<td>Yes Yes Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Schnieder 2021[23]</td>
<td>Retrospective cohort</td>
<td>No No Yes Yes</td>
<td>Yes Yes No</td>
<td>No</td>
</tr>
<tr>
<td>Seamon 2019[24]</td>
<td>Retrospective cohort</td>
<td>Yes Yes Yes Yes</td>
<td>Yes Yes Yes</td>
<td>Unclear</td>
</tr>
<tr>
<td>Waehler 2021[27]</td>
<td>Prospective cohort</td>
<td>Yes Yes Yes Yes</td>
<td>Yes Yes Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Zhang 2020[28]</td>
<td>Prospective cohort</td>
<td>No Yes Yes Yes</td>
<td>Yes Yes Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Fearon 2012[14]</td>
<td>Cross-sectional</td>
<td>Yes Yes Unclear Yes</td>
<td>Yes Yes Yes</td>
<td>N/A</td>
</tr>
<tr>
<td>Taylor-Rowan 2019[25, 26]</td>
<td>Cross-sectional</td>
<td>Yes Yes Yes Yes</td>
<td>Yes Yes Yes</td>
<td>N/A</td>
</tr>
</tbody>
</table>

Footnotes
1. Selected group (haemorrhage only)
2. Frailty Score may include post stroke diagnoses
3. Unclear how modified Rankin Scale was assessed
4. Only those receiving mechanich thrombectomy
5. Patients excluded on basis of age, pre-stroke modified Rankin Scale and comorbidity
6. Complete case analysis data only

![Forest plot from meta-analysis of frailty prevalence data.](https://academic.oup.com/ageing/article/51/3/afac064/6554095)

Figure 1. Forest plot from meta-analysis of frailty prevalence data.

When studies looking only at haemorrhagic stroke were excluded, prevalence was 23.9% (95%CI: 14.6–33.1%; $I^2$: 95.2%; 11 studies; 24,716 participants). When studies looking only at patients receiving thrombectomy were excluded prevalence was 26.1% (95%CI: 18.7–33.5%; $I^2$: 88.1%; 10 studies; 26,072 participants).

Only half of the included abstracts reported the prevalence of frailty among their included participants, ranging from 24.8 to 68.4%. Re-running the frailty prevalence analysis including the abstract data suggested a prevalence of 28.4% (95%CI: 20.1–36.7%; $I^2$: 95.8%; 19 reports; 29,722 participants).
Prevalence and implications of frailty in acute stroke

Table 4. Summary of association between pre-stroke frailty and outcomes (published papers)

<table>
<thead>
<tr>
<th>Frailty measure</th>
<th>Pre-specified outcomes of interest</th>
<th>Other reported outcomes</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>In-hospital mortality</td>
<td>Mortality (at follow-up)</td>
</tr>
<tr>
<td>Frailty Index (7 studies)</td>
<td>□</td>
<td>■■</td>
</tr>
<tr>
<td>Fried criteria (1 study)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>HFRS (4 studies)</td>
<td>□</td>
<td>■■</td>
</tr>
<tr>
<td>Other (2 studies)</td>
<td>■</td>
<td></td>
</tr>
</tbody>
</table>

Footnotes
■ = statistically significant positive association in a paper between frailty and outcome on adjusted analyses
□ = outcome examined in paper, but no statistically significant positive association between frailty status and outcome on adjusted analyses
Disability = higher modified Rankin Scale or poor functional outcome
Impairment = higher National Institute for Health Stroke Scale results
* = only for individuals treated with intravenous thrombolysis
HR QoL = Health Related Quality of Life

Association between frailty and outcomes

The relationship between frailty status and outcomes after stroke was inconsistently reported across the included studies, we sought data from all 16 of the identified papers. Three papers did not report any of our pre-specified outcomes of interest [14, 25, 27]. In a fourth paper the outcomes for those experiencing stroke were not reported separately from those with TIA [19]. A tabular summary of the association between frailty and outcomes is reported in Table 4, with additional information in Appendix 6 (Supplementary data are available in Age and Ageing online) quantifying the associations between frailty and mortality and length of stay.

Mortality: seven studies examined the association between frailty status and mortality risk over a range of follow-up periods [13, 15, 16, 20, 21, 23, 28]. Two studies specifically considered in-hospital mortality and found no association with frailty, using a frailty index and the HFRS [20, 23]. Another reported on mortality at 28 days and found those who were frail had a higher rate of mortality and that increasing frailty remained independently associated with mortality after adjustment for cardiovascular risk factors and stroke severity, using CFS [13]. Mortality at 90 days was higher in those who were frail compared to the non-frail participants in two studies, using frailty index and HFRS respectively [16, 23]. Mortality at 180 days was higher in a single study using HFRS [28]. Mortality at 6–8 months follow-up was associated with increased frailty, odds ratio (OR) 2.97 (95%CI: 1.52–5.8), in one study, using a frailty index [15]. The study, which used mRS as a measure of frailty reported that mortality increased as mRS increased [21]. For seven papers [13, 15, 16, 19, 21, 23, 26], data were suitable to allow a summary analysis, the estimate of association between frailty and mortality was OR: 3.71 (95%CI: 2.41–5.70).

Length of hospital stay: four studies examined the association between frailty status and hospital length of stay, three of which identified frailty (measured by frailty index) as associated with longer stays [18, 20, 24] and one found no difference in length of stay between low, moderate and high frailty risk individuals using HFRS [23].

Functional outcome/disability: six studies evaluated the association between frailty status and functional outcome or level of disability [15, 16, 18, 20, 22, 23]. Four studies found a statistically significant association between frailty and poorer functional outcome (mRS; [15, 16, 22, 23]). However, one study found no association [18] and the final study reported that the association was not present after adjustment [20].

Discharge destination: only one study looked at discharge destination, with an increasing likelihood of discharge to long-term care as frailty increased (non-frail 18.5% versus pre-frail 28% versus frail 46.9%) [24].

Other outcomes reported: there was limited examination of other outcomes’ association with frailty status. Impairment, measured using NIHSS, was associated with frailty in two studies [17, 27] but in three studies [16, 23, 25] there was no association after adjustment. One study suggested that frailty may moderate acute treatment effects, reporting that every one-point increase in CFS was independently associated with a one-point reduction in post-thrombolysis improvement, using NIHSS [13]. One study reported health-related quality of life, measured using EQ-5D, at 18 months of follow-up, reporting lower scores in those who were frail compared to those who were pre-frail or robust [27]. Post-stroke cognitive impairment was associated with frailty in one study [26].

The abstracts reported associations with in-hospital mortality, poorer recovery or neurological outcome, reduced chance of returning home/increased risk of new
institutionalisation, longer length of stay and complications after stroke. The mRS was commonly used as an outcome measure associated with frailty (Appendix 7, Supplementary data are available in Age and Ageing online).

Frailty and pre-stroke function or comorbidity
Six studies reported on the distribution of pre-stroke mRS in their cohorts (Appendix 8, Supplementary data are available in Age and Ageing online; [13, 14, 17, 22, 25, 27]). Differing approaches were used to assess for the association of mRS with frailty. Two studies found no statistical association between frailty and pre-stroke mRS [13, 22]. Correlation between the frailty measure and pre-stroke mRS was moderate [14, 25]. In one study there was increasing mean pre-stroke mRS across robust, pre-frail and frail states [27]. The proportions classified as having pre-stroke disability and pre-stroke frailty differed in three studies [14, 17, 25], whereas there was no significant difference in one study [22].

Of the six studies reporting quantitative measures of comorbidity, correlation was moderate. Four studies showed differences in comorbidity with increasing frailty [19, 24, 27] but the differences were not all in a ‘dose response’ pattern (Appendix 8, Supplementary data are available in Age and Ageing online; [23]).

Discussion
Through a synthesis of the published evidence, we have shown that frailty is common in acute stroke. We estimate that at least one in four people presenting with a stroke are living with frailty, this increases to two in three if we include pre-frailty. We have also shown that pre-stroke frailty is associated with poor outcomes including death, disability and increased length of stay. Accepting all the caveats of our post hoc analysis, we estimated that the presence of frailty increased odds of death from stroke by almost four times. Finally, we have shown that while pre-stroke frailty is related to the concepts of pre-stroke function and pre-stroke comorbidity, the three are not equivalent and frailty measures seem to be a distinct construct.

Findings in context
For a condition as common and prognostically important as frailty, the number of relevant studies was disproportionately limited. A similar pattern is seen for studies looking at related older adult syndromes in stroke, for example delirium [41] and sarcopenia [42]. Our limited understanding of frailty and cerebrovascular disease in general was highlighted in a recent narrative review that outlined important future directions for frailty research in stroke [43]. The areas highlighted align with the data gaps seen in our review: a better understanding of how to assess for frailty and the challenges of assessment in stroke; more data on the effect of frailty on multimodal outcomes and studies assessing how we can use frailty assessment to improve stroke-care. We would hope the landscape around frailty and stroke is changing and we note that 12 of the 14 included studies were published in the last three years, suggesting that the topic is of increasing interest.

Our focus was pre-stroke frailty, as we recognised that an understanding of frailty status could help in hyperacute treatment decisions and support person centred care. A review of the epidemiology of frailty in a post-stroke population suggested a population prevalence of 22% frailty and 49% pre-frailty [44]. These figures are similar to our data. One may expect the prevalence to increase, particularly as the stroke event and related impairments could move someone from the pre-frail state to frank frailty. However, as pre-stroke frailty was so strongly associated with mortality, it seems plausible that many people living with pre-stroke frailty do not survive their stroke event and so will not feature in the community estimates of post stroke frailty.

Clinical implications
At the time of writing, pre-stroke frailty is not routinely measured in national stroke audits and registers such as the UK sentinel Stroke National Audit Programme (SSNAP), RiksStroke in Sweden or SITS-MOST (Safe Implementation of Thrombolysis in Stroke Monitoring Study). However, these registers all collect pre-stroke function as measured by the mRS. Our data suggest that assessment of frailty may offer additional information to the pre-stroke mRS assessment. Problems with pre-stroke mRS are well recognised [14]. One could even argue that pre-stroke frailty assessment could replace pre-stroke mRS. Pre-stroke mRS is used as exclusion criterion, case-mix adjuster and prognostic tool—our data suggest that pre-stroke frailty assessment could fulfil all these roles. A frailty tool such as the CFS offers a similar ordinal, hierarchical structure to mRS and could be incorporated into systems that already use pre-stroke.

A motivation for this review was the changing treatment landscape in stroke. A key component of evidence-based stroke-care is the acute stroke unit (ASU; [45]). ASUs offer multidisciplinary assessment and intervention that has many similarities to the CGA that can be effective for people living with frailty [46]. Recent developments in acute and hyperacute stroke place an increasing emphasis on interventions such as mechanical thrombectomy. Although these treatments are lifesaving or life changing for many, their safety and efficacy in people living with advanced frailty is less certain. Our review included three studies describing frailty and thrombectomy and all came to the same conclusion that outcomes were considerably poorer in people living with frailty. An unanswered question is whether these interventions offer any relative benefit in a frail population who tend to have poor outcomes regardless of treatment.

Research implications
Our review has highlighted many important evidence gaps around frailty and stroke. If frailty is to become part of the baseline stroke assessment, we need further research comparing the different frailty measures in stroke populations. We
Prevalence and implications of frailty in acute stroke

Conclusions

Pre-stroke frailty is common and prognostically important. Assessment of pre-stroke frailty could be used to inform hyperacute treatment decisions and may have greater utility than commonly employed measures such as pre-stroke mRS.

Declaration of Conflicts of Interest: None.

Declaration of Sources of Funding: JKB is supported by a Joint NHS Education for Scotland/Chief Scientist Office (NES/CSO) Postdoctoral Clinical Lectureship. The funders played no part in the conduct of this review.

References


Supplementary Data: Supplementary data mentioned in the text are available to subscribers in Age and Ageing online.

Received 3 September 2021; editorial decision 14 December 2021